A B S T R A C T Mevinolin reduces cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The safety and effectiveness of this agent was evaluated in a double-blind, placebo-controlled study in One subject (12.5 mg) was withdrawn because of abdominal pain and diarrhea. These results suggest that if long-term safety can be demonstrated, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase are likely to prove useful in the treatment of hypercholesterolemia. INTRODUCTION Elevated serum cholesterol is a major factor in the development of atherosclerosis and coronary heart disease (1, 2). There is a substantial and currently unsatisfied need for safe, well tolerated therapy capable of effecting large reductions in serum cholesterol.
INTRODUCTION
Elevated serum cholesterol is a major factor in the development of atherosclerosis and coronary heart disease (1, 2). There is a substantial and currently unsatisfied need for safe, well tolerated therapy capable of effecting large reductions in serum cholesterol.
Mevinolin [MK-803, 1,2,6,7,8,8a-hexahydro-f3,6-dihydroxy-2,6-dimethyl-8-(2-methyl-i -oxobutoxy) -1-Received for publication 21 September 1981 and in revised form 14 December 1981. naphthalene-heptanoic acid 6 -lactone], a fermentation product derived from Aspergillus terreus, is rapidly converted in vivo to the corresponding hydroxy acid, mevinolinic acid, which is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (E.C. 1.1.1.34; HMG-CoA' reductase) (3); this enzyme catalyzes the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, which is the rate-limiting step in the cholesterol synthesis pathway (4) . Mevinolin lowers serum cholesterol in dogs (3, 5) , and in a pilot study in healthy men it was well tolerated and exerted a rapid and substantial cholesterol-lowering effect (6) .
The purpose of this investigation was to estimate the safety, tolerability, and efficacy of mevinolin at various doses in healthy normocholesterolemic volunteers, and thereby to obtain data required for the design of subsequent studies in hypercholesterolemic patients. Efficacy was assessed by determination of cholesterol in high density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL), and apolipoprotein B and triglycerides, over a 4-wk treatment period. Safety and tolerability were assessed by routine clinical and laboratory measurements. In addition, because cholesterol is the precursor of all steroid hormones, the possibility that mevinolin could reduce steroidogenesis was investigated by meal Abbreviations used in this paper: CPK, creatine phosphokinase; HDL Analytical methods. The laboratories in the five centers used their usual methods for total cholesterol, HDL cholesterol, triglycerides, plasma cortisol, plasma testosterone, 17-hydroxysteroids, and 17-ketosteroids. These are given in Table I . HDL cholesterol was directly measured using precipitation methods, and VLDL and LDL cholesterol were estimated according to the approximation of Friedewald et al. (21) : total cholesterol = (HDL + LDL + VLDL) cholesterol, where VLDL cholesterol concentration = 0.80 triglycerides concentration (in SI units). The validity of this approximation under the conditions of this study was checked in two centers (Cardiff and London), which also measured VLDL directly, using double precipitation methods (22, 10) . Serum for determination of apolipoprotein B was frozen and shipped to Rahway, NJ, where the radial immunodiffusion method of Sniderman et al. (23) was used. Laboratory safety tests were performed using routine automated methods. Dunn (24) after removing the effect of differences between centers (25) .
In addition, the data from the mevinolin bid groups were assessed using a regression analysis. The regression analysis was performed using a log transformation (i.e., to obtain the values 1, 2, 3, 4) on the independent variable (dose of mevinolin). A significant regression coefficient can be interpreted as an indication of a dose-related response. For the measurements of total, HDL, and LDL cholesterol, triglycerides and apolipoprotein B, percent change from base line was also assessed.
RESULTS
57 of the 59 subjects completed the study. AN 38 (12.5 mg bid) was withdrawn on day 21 because of adverse effects (see below), and AN 41 (6.25 mg bid) withdrew for personal reasons on day 25. Because of a dispensing error, AN 10 (50 mg bid) received medication on days 21-28 intended for AN 12 (12.5 mg bid), and vice versa, and the day 29 values for these two subjects were therefore excluded from the analysis. According to the subject diaries, 99% of the prescribed capsules were taken, indicating good compliance.
Analysis of variance revealed no significant centerby-treatment interactions; accordingly, the results from the five centers were pooled (25) . (Fig. 1) , (vs. placebo at day 29, P < 0.01), which was entirely attributable to a reduction in LDL cholesterol concentration of 35-45% (Figs. 1, 2) ; there was no significant change in HDL cholesterol, VLDL cholesterol, and triglycerides (Fig. 1) . The reduction in LDL cholesterol was evident after 3 d of treatment and was essentially complete after 14 d (Fig. 3) . LDL cholesterol tended to fall a little faster at the higher doses, but at the end of treatment, the effect of the top dose, 50 mg bid, was only slightly and not significantly greater than that of the lowest dose, 6 .25 mg bid and there was no significant regression of effect on dose. (Figs. 1, 2 ). 25 The magnitude of the responses to treatment differed from center to center (Figs. 2, 4 ). This effect was statistically significant (P < 0.05 by analysis of variance) for day 29 apolipoprotein B but not day 29 LDL cholesterol, and for LDL cholesterol at several of the earlier time points. When the posttreatment results on all the bid doses were pooled, a positive correlation was observed between response, expressed as absolute fall in LDL cholesterol concentration at the end of treatment, and base line LDL cholesterol (r = 0.34, P = 0.045). When response was expressed as percentage reduction, there was no correlation (r = 0.11, P = 0.55).
Plasma cortisol and testosterone concentrations and urinary excretion of 17-hydroxysteroids and 17-ketosteroids were not significantly affected by mevinolin, although posttreatment values were generally slightly lower than base line in the active treatment groups (Table II) 
DISCUSSION
As is expected in a multicenter study, the responses to treatment differed quantitively from center to center. The use of a balanced design and the absence of any significant center-by-treatment interactions permitted the pooling of the data without introduction of bias (25) . Lipid-lowering drugs have not often been investigated in normocholesterolemic volunteers, but the mean falls in serum cholesterol observed in this study are probably larger than can be obtained with any approved lipid-lowering agent, with the exception of cholestyramine and other bile acid sequestrants, which can produce a response of similar magnitude, but which (because of their bulk and taste) are poorly tolerated by many patients (26) . Although caution is warranted when extrapolating results obtained in normal volunteers to the clinical situation, it is worth noting that a 35-45% reduction in LDL cholesterol, as observed in this study, would be sufficient for many hypercholesterolemic patients. It is also of interest that in dogs synergism between mevinolin and bile acid sequestrants has been reported (5).
The cholesterol-lowering effect of mevinolin was achieved by a reduction in the atherogenic LDL frac- 24 h after a single dose of mevinolin in healthy volunteers. The lack of regression of effect on dose indicates that all the doses used in this study lie near the top of the dose-response curve in normocholesterolemic individuals when given bid. Insofar as one objective of the study was to define the dose-response curve, it is evident that we underestimated the potency of mevinolin.
The incidence, nature, and intensity of the adverse events noted in this study, not all of which were necessarily drug related, are considered quite acceptable relative to the potential therapeutic benefits, taking into account the fact that the top dose used was eight times the dose found to produce near-maximal pharmacological effects. The lack of a statistically significant effect of mevinolin on plasma testosterone and cortisol, and 17-hydroxysteroid and 17-ketosteroid excretion, indicates that steroidogenesis is probably not affected to any clinically important degree by mevinolin under normal conditions. However, there appeared to be a trend towards a reduction of these variables, and the possibility that a clinically significant effect might be observed when steroidogenesis is proceding at a high rate (e.g., during stress) cannot be ruled out.
None of the lipid-lowering agents currently in clinical use exert any major effect on the cholesterol synthesis pathway. Earlier attempts to reduce serum cholesterol by inhibiting its synthesis involved the use of drugs such as triparanol (MER-29) and AY-9944, which inhibit late steps in the cholesterol synthesis pathway (29, 30) . Triparanol was introduced into clinical use but was withdrawn because of serious toxic effects, some of which may have been related to the build-up of the sterol intermediate desmosterol (31, 32) . Inhibition of HMG-CoA reductase could not cause build-up of sterol intermediates. ML-236B, a structurally related compound that is obtained from a differnt microorganism (33) and is a less potent inhibitor of HMG-CoA reductase (3), has recently been reported to be effective in the treatment of hypercholesterolemia (34, 35) . In our short-term study, mevinolin was safe and generally well tolerated (particularly at the lower doses), and was very potent as a cholesterol-lowering agent, both in terms of response attained and on a milligram basis. If safety during long-term use can be demonstrated, inhibitors of HMG-CoA reductase may well provide an important advance in the treatment of hypercholesterolemia.
